# Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection

> **NCT05857163** · PHASE3 · COMPLETED · sponsor: **TenNor Therapeutics (Suzhou) Limited** · enrollment: 700 (actual)

## Conditions studied

- H.Pylori Infection

## Interventions

- **DRUG:** Rifasutenizol capsules
- **DRUG:** Rabeprazole sodium enteric-coated tablets
- **DRUG:** Amoxicillin Capsules
- **DRUG:** Clarithromycin placebo tablets
- **DRUG:** Bismuth potassium citrate placebo capsules
- **DRUG:** Clarithromycin tablets
- **DRUG:** Bismuth potassium citrate capsules
- **DRUG:** Rifasutenizol placebo capsules

## Key facts

- **NCT ID:** NCT05857163
- **Lead sponsor:** TenNor Therapeutics (Suzhou) Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-18
- **Primary completion:** 2023-12-24
- **Final completion:** 2024-03-26
- **Target enrollment:** 700 (ACTUAL)
- **Last updated:** 2025-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05857163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05857163, "Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05857163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*